NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors - Michael S. Chang, MD; Jordan T. Said, MD; Elliot H. Akama-Garren, PhD; Nicole Trepanowski, MD; Ai-Tram N. Bui, MD; Anita Giobbie-Hurder, MS; Nicole R. LeBoeuf, MD, MPH; Rebecca I. Hartman, MD, MPH (JAAD International)